Agenus Inc. (NASDAQ:AGEN) Stock Rating Upgraded by BidaskClub

Agenus Inc. (NASDAQ:AGEN) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Monday, July 24th.

Several other brokerages also recently commented on AGEN. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Zacks Investment Research raised Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Wednesday, July 5th. HC Wainwright set a $5.00 price objective on Agenus and gave the stock a “hold” rating in a research note on Saturday, May 6th. Finally, Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Agenus in a research note on Sunday, April 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Agenus has a consensus rating of “Hold” and an average target price of $5.88.

Agenus (AGEN) opened at 3.57 on Monday. The stock’s market cap is $355.97 million. The firm has a 50-day moving average price of $4.25 and a 200 day moving average price of $3.90. Agenus has a 52-week low of $3.20 and a 52-week high of $7.49.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $6.66 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The firm’s revenue was down 36.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.33) EPS. Equities analysts anticipate that Agenus will post ($1.13) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/agenus-inc-nasdaqagen-stock-rating-upgraded-by-bidaskclub-updated-updated-updated.html.

Hedge funds have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC increased its stake in Agenus by 0.6% in the second quarter. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company’s stock valued at $800,000 after buying an additional 1,283 shares in the last quarter. American International Group Inc. increased its stake in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,984 shares in the last quarter. Quotient Investors LLC increased its stake in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 3,800 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Agenus by 6.7% in the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 4,006 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its stake in Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 6,101 shares in the last quarter. 41.54% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply